Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight by an average of 12% after 72 weeks.

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Lawsuits from at least 26 patients have been filed in Marion County against Eli Lilly and Co. for its marketing of the drugs ...

At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...

Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.